Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

KORE Telematics certifies MedApps telehealth solutions for use on its network

American Telemedicine Association Mid-Year Meeting—KORE Telematics, the world’s largest digital wireless services provider specializing in machine-to-machine (M2M) communications, today announced that MedApps telehealth solutions are now certified for use on the KORE network.

24 Sep 2009

Computational models form basis to design the device for recreating kidney function

Researchers from Mount Sinai School of Medicine and two other academic institutions have received federal funding to systematically assemble functional human kidney tissue from tissue modeled on a computer. If successful, the research-which ties together several emerging technologies including virtual tissue modeling and nanofabrication-could lead to a more predictable way for researchers to engineer tissue outside the body and, consequently, to screen for new drugs.

24 Sep 2009

VisEn launches new imaging agent for monitoring key hypertension and renal disease biomarker

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new ReninSense680(TM) FAST imaging agent for measuring and monitoring a key hypertension and renal disease biomarker in vivo.

24 Sep 2009

Research study links high-fructose diet to increased blood pressure in men

A high-fructose diet raises blood pressure in men, while a drug used to treat gout seems to protect against the blood pressure increase, according to research reported at the American Heart Association's 63rd High Blood Pressure Research Conference.

24 Sep 2009

Results of OASIS clinical trial reported by Cardiovascular Systems

Two-year follow-up of patients in the first-ever prospective, multi-center clinical trial evaluating a plaque removal product show promising results after treatment with the Diamondback 360® PAD System, a minimally invasive catheter system that removes hardened plaque to restore blood flow in arteries.

23 Sep 2009

Report on evidence-based disease prevention programs released by TFAH and NYAM

Trust for America's Health (TFAH) and The New York Academy of Medicine (NYAM) released a new report today featuring a range of evidence-based disease prevention programs that have shown results for improving health and reducing costs in communities.

22 Sep 2009

Bayer's regorafenib showed 50% stabilization rate in RCC patients

Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC).

22 Sep 2009

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Three new HealthPartners Research Foundation studies will examine ways to prevent and treat childhood obesity and hypertension. One study will look at interventions to prevent obesity in children ages 5-9, another will focus on obesity prevention in children ages 2-5, while another will examine hypertension in children and adolescents, including the quality and cost of care.

21 Sep 2009

Vitae Pharmaceuticals initiates Phase 1 clinical trial of its novel cardiovascular agent

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.

21 Sep 2009

Phytel releases new version of its web-based Proactive Patient Outreach Solution

Phytel, the leading provider of information technology that empowers physician-led health improvement, today announced that version 5 of its web-based Proactive Patient Outreach Solution has been released and fully deployed to all of its customers.

21 Sep 2009

Hypertension Diagnostics' revenue decreases by 9.2% for the fiscal year 2009

Hypertension Diagnostics, Inc. (OTCBB: HDII), today announced audited financial results for the fiscal year ended June 30, 2009.

21 Sep 2009

Treatment costs for diabetes care are higher in Texas than other states

The Texas Business Group on Health (TBGH), a non-profit business association, today released its annual report on the prevalence, cost and quality of care for Texans with Type 2 diabetes.

18 Sep 2009

Study compares annual healthcare costs of diabetic and non-diabetic individuals

Risk factors for metabolic syndrome, such as obesity, high blood pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-fold, or about $2,000 per year. For each additional risk factor those costs rise an average of 24%, according to an illuminating article in a recent issue of Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc.

18 Sep 2009

FDA approves Valturna tablets for treating high blood pressure

The US Food and Drug Administration (FDA) has approved Valturna((R)) (aliskiren and valsartan) tablets, the first and only medicine to target two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), an important regulator of blood pressure.

18 Sep 2009

Health policy research roundup

Implementation Choices for the Children's Health Insurance Program Reauthorization Act of 2009 - This report examines two key areas of the implementation process of the Children's Health Insurance Program Reauthorization Act (CHIPRA) of 2009 - outreach and enrollment, and quality of care - and issues a set of recommendations. "Recommendations include: giving funding priority to states that will adopt or maintain key simplifications… ensuring quality measures focus on priority health needs for children, and building quality measurement and improvement capabilities into electronic health information systems, among others," according to a Commonwealth Fund description of the report (Simpson, Fairbrother, Touschner and Guyer, 9/10).

18 Sep 2009

Mayo Clinic Women's HealthSource discusses myths and facts about ovarian cancer

But not all the news about ovarian cancer is grim. Incidence is declining. Doctors are learning more about early symptoms and more effective treatments. The September issue of Mayo Clinic Women's HealthSource looks at myths and facts about ovarian cancer.

17 Sep 2009

Study focuses on hypertension

How high blood pressure develops and the effects it has on the body are the focus of a two-part study underway at Penn State and Johns Hopkins University that will look at hypertension in the human body and in the laboratory.

17 Sep 2009

Protein kinase Erk3 plays a critical role in intrauterine growth and lung maturation

Dr. Sylvain Meloche, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and his colleagues have uncovered the critical role played by the protein kinase Erk3 in fetal growth potential and lung maturation.

17 Sep 2009

Aviva Select series of Disease Management and Wellness programs launched

Avivia Health announces Avivia Select, a new series of affordable Disease Management and Wellness programs specifically designed to help companies provide important new benefits to their employees. Avivia Health is the only national provider of Disease Management and Wellness Solutions based on 60 years of evidence-based care by parent organization Kaiser Permanente.

16 Sep 2009

Palatin Technologies to announce clinical trial results of PL-3994

Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will be presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.

15 Sep 2009